Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2024.01.004 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Alexandra Hillyer und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Toronto, Toronto, ON. Hauptthemen laut MEDLINE: Hematologic Neoplasms, COVID-19, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche Diagnostics Corp.
Abstract (Originalsprache)
BACKGROUND: Patients with hematological cancers have increased COVID-19 morbidity and mortality, and these patients show attenuated vaccine responses. This study aimed to characterize the longitudinal humoral immune responses to COVID-19 vaccination in patients with hematological malignancies. PATIENTS AND METHODS: We conducted a prospective cohort study, collecting samples from March 2021 to July 2022, from patients seen at a cancer treatment center in London, Ontario, Canada, who met the following eligibility criteria: age ≥18 years, diagnosed with a hematological malignancy, recipient of a COVID-19 vaccine during the study period, and able to provide informed consent. RESULTS: Median anti-S titers (MST) were 0.0, 64.0, and 680.5 U/mL following first (V1), second (V2), and third (V3) vaccine doses, respectively. Patients with lymphoid malignancies' response to vaccination was attenuated compared to myeloid malignancy patients after V2 and V3 (P 24 months (MST 1660.5, P = .0025) prior to vaccination. V3 significantly increased antibody titers compared to V2 for patients less than 3 months from treatment. Increasing age was associated with smaller antibody response following V2 (P .05). CONCLUSION: We report an attenuated serologic response to COVID-19 vaccination in our study population of patients with hematological malignancy. The immune response to vaccination was affected by patient age, diagnosis, treatment, and timing of treatment exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Toronto, Toronto, ON.
- McGill University, Montreal, QC.
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON.
- Schulich School of Medicine and Dentistry, Western University, London ON.
- Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON.
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON. Electronic address: chai.phua@lhsc.on.ca.
Förderung
- Roche Diagnostics Corp
Zitieren
APA
Hillyer, A., Quint, A., Ghassemian, A., Joh-Carnella, N., Knauer, M. J., Dawd, D., Lazo-Langner, A., Mangel, J., Lam, S., Abdoh, H., Xenocostas, A., Deotare, U., Saini, L., Foster, C., Louzada, M., Ho, J., Chin-Yee, I., & Phua, C. W. (2024). Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.01.004
Vancouver
Hillyer A, Quint A, Ghassemian A, Joh-Carnella N, Knauer MJ, Dawd D, et al. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.01.004
BibTeX
@article{Hillyer2024,
author = {Hillyer, Alexandra and Quint, Anthony and Ghassemian, Artin and Joh-Carnella, Nicolette and Knauer, Michael J and Dawd, Danny and Lazo-Langner, Alejandro and Mangel, Joy and Lam, Selay and Abdoh, Husam and Xenocostas, Anargyros and Deotare, Uday and Saini, Lalit and Foster, Cheryl and Louzada, Martha and Ho, Jenny and Chin-Yee, Ian and Phua, Chai W},
title = {Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2024.01.004}
}
EUVIMED